High Specialty

High Speciality

At the forefront of healthcare

With the purpose of making health accessible and improving the well-being of the population, in 2005 we began the development and production of highly specialized drugs to treat chronic degenerative diseases.

We developed insulin glargine, a biotech drug; antiretrovirals for human immunodeficiency virus (HIV); as well as other treatments for diseases such as cancer and multiple sclerosis.

See our full portfolio

View catalog
High Specialty